国新健康(000503) - 2019 Q3 - 季度财报

Financial Performance - Operating revenue for the reporting period was CNY 22,171,801.88, representing a decrease of 8.65% year-on-year[11]. - Net profit attributable to shareholders of the listed company was a loss of CNY 33,865,233.97, a decline of 35.46% compared to the same period last year[11]. - Basic earnings per share were CNY -0.0377, down 35.46% year-on-year[11]. - The weighted average return on net assets was -2.83%, a decrease of 1.04% compared to the previous year[11]. - The company reported a loss of CNY 6,284,494.11 from fair value changes in financial assets during the reporting period[46]. - The net profit for the current period is CNY -147,478,303.38, compared to CNY -115,856,429.60 in the previous period, indicating a deeper loss[96]. - The net profit attributable to the parent company is CNY -146,243,736.28, compared to CNY -113,272,856.82 in the previous period, showing a worsening financial performance[96]. - Total comprehensive income for the current period is CNY -153,599,902.75, compared to CNY -100,002,785.44 in the previous period[113]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,110,134,819.01, a decrease of 13.29% compared to the end of the previous year[11]. - Total current assets decreased from 768.71 million to 649.92 million, a decline of approximately 15.4%[60]. - Total non-current assets decreased from 511.64 million to 460.22 million, a decline of approximately 10%[60]. - Total current liabilities decreased from 62.73 million to 46.12 million, a decline of approximately 26.6%[63]. - Total liabilities remained the same at 46.12 million, indicating no change[63]. - Total equity attributable to shareholders decreased from 1.21 billion to 1.06 billion, a decline of approximately 12.5%[66]. - Total liabilities and equity decreased from 1.28 billion to 1.11 billion, a decline of approximately 13.2%[66]. Cash Flow - The net cash flow from operating activities was a negative CNY 141,840,199.66, a significant decrease of 922.41%[11]. - Cash inflow from operating activities totaled 62,169,920.81 yuan, down from 171,355,554.28 yuan year-over-year[134]. - Cash received from other operating activities was 354,201,920.15 yuan, showing a significant increase compared to 13,766,290.33 yuan in the previous period[145]. - Cash paid to employees was 7,213,246.32 yuan, up from 5,770,082.47 yuan in the previous period[145]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 57,247[15]. - The largest shareholder, Zhonghai Heng Industrial Development Co., Ltd., held 26.22% of the shares, totaling 235,702,593 shares[15]. - The controlling shareholder has cumulatively increased its holdings by 4,333,200 shares, accounting for 0.48% of the total share capital, with a total investment of approximately 100 million yuan[32]. Investments and Acquisitions - The company purchased a 99.01% partnership interest in Shenzhou Borui for a cash price of RMB 376 million, adjusted to RMB 356 million due to a debt of RMB 20 million assumed by Guoxin Health[36]. - The company transferred 100% equity of Zhejiang Haihong for RMB 13.78 million and 99.7% equity of Haihong Assets for RMB 7.28 million to its controlling shareholder, Zhonghai Heng, while Zhonghai Heng will repay debts of RMB 13.59 million and RMB 73.87 million respectively[36]. - The company has been planning a major asset restructuring since June 2018, intending to acquire 99.3267% of Jingyi Technology's shares through a share issuance[32]. - The company received a letter from Jingyi Technology regarding the termination of the major asset restructuring due to the inability to reach consensus on key terms[32]. Government Support - The company received government subsidies amounting to CNY 191,225.25, primarily from VAT exemptions for small and micro enterprises[11]. - Other income rose by 129.63% from RMB 83,275.10 to RMB 191,225.25, mainly due to VAT exemptions for small and micro enterprises[25]. Research and Development - Research and development expenses for the current period are CNY 3,674,492.49, indicating ongoing investment in innovation[93]. - The company incurred research and development expenses of 1,000,000.00 yuan[129]. Compliance and Governance - The company has not engaged in any non-operating fund occupation by controlling shareholders or related parties during the reporting period[53]. - The company has not provided any external guarantees that violate regulations during the reporting period[52]. - The company is currently fulfilling its commitments without any violations reported[41].